Avro, a life sciences startup in Y Combinator’s current batch, is banking on a method to deliver medications to populations unable to swallow or chew — It will administer them through the skin. Starting with allergy medications, the startup is developing skin patches that release drugs commonly used in seasonal allergies for children. The patches act much like nicotine patches,… Read More
Source: Tech Crunch